Robert Redfield - 09 Jul 2026 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)

Reporting relationship: Chief Medical Officer
Issuer ticker: TRAW
Reported as of: 09 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jul 2026, 20:23:52 UTC
Prior SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Redfield

Key filing fact

Robert Redfield filed Form 4 for Traws Pharma, Inc. (TRAW) on 14 Jul 2026.

Key facts

This page summarizes Robert Redfield's Form 4 filing for Traws Pharma, Inc. (TRAW).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jul 2026, 20:23.

Change

Previous filing in this sequence was filed on 10 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002018274 Primary reporting owner

Redfield Robert

Relationship: Chief Medical Officer
Address: C/O TRAWS PHARMA, INC., 12 PENNS TRAIL, NEWTOWN
Signature: /s/ Robert Redfield
Signature date: 14 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAW transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +84,000
Change %
Price: $0.000000^*
Shares after: 84,000
Date: 09 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,000
Exercise price: $0.6800
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.